122 related articles for article (PubMed ID: 32027395)
1. Sub-acute toxicological and behavioural effects of two candidate therapeutics, cinnamaldehyde and eugenol, for treatment of ESBL producing-quinolone resistant pathogenic Enterobacteriaceae.
Dhara L; Tripathi A
Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):977-988. PubMed ID: 32027395
[TBL] [Abstract][Full Text] [Related]
2. Cinnamaldehyde: a compound with antimicrobial and synergistic activity against ESBL-producing quinolone-resistant pathogenic Enterobacteriaceae.
Dhara L; Tripathi A
Eur J Clin Microbiol Infect Dis; 2020 Jan; 39(1):65-73. PubMed ID: 31624984
[TBL] [Abstract][Full Text] [Related]
3. The use of eugenol in combination with cefotaxime and ciprofloxacin to combat ESBL-producing quinolone-resistant pathogenic Enterobacteriaceae.
Dhara L; Tripathi A
J Appl Microbiol; 2020 Dec; 129(6):1566-1576. PubMed ID: 32502298
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of combined antibacterial effects of eugenol, cinnamaldehyde, thymol, and carvacrol against E. coli with an improved method.
Pei RS; Zhou F; Ji BP; Xu J
J Food Sci; 2009 Sep; 74(7):M379-83. PubMed ID: 19895484
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
[TBL] [Abstract][Full Text] [Related]
6. Plasmid-mediated quinolone resistance among extended spectrum beta lactase producing Enterobacteriaceae from bloodstream infections.
Domokos J; Kristóf K; Szabó D
Acta Microbiol Immunol Hung; 2016 Sep; 63(3):313-323. PubMed ID: 27539331
[TBL] [Abstract][Full Text] [Related]
7. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. isolates in Mongolia.
Kao CY; Udval U; Huang YT; Wu HM; Huang AH; Bolormaa E; Yan JJ; Urangoo Z; Batbaatar G; Khosbayar T; Wu JJ
J Microbiol Immunol Infect; 2016 Oct; 49(5):692-700. PubMed ID: 26194952
[TBL] [Abstract][Full Text] [Related]
9. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
Xiong Z; Zhu D; Zhang Y; Wang F
Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of flomoxef against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Korea.
Jung Y; Lee SS; Song W; Kim HS; Uh Y
Diagn Microbiol Infect Dis; 2019 May; 94(1):88-92. PubMed ID: 30658867
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum β-lactamase.
Morfín-Otero R; Mendoza-Olazarán S; Silva-Sánchez J; Rodríguez-Noriega E; Laca-Díaz J; Tinoco-Carrillo P; Petersen L; López P; Reyna-Flores F; Alcantar-Curiel D; Garza-Ramos U; Garza-González E
Microb Drug Resist; 2013 Oct; 19(5):378-83. PubMed ID: 23725513
[TBL] [Abstract][Full Text] [Related]
12. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
[TBL] [Abstract][Full Text] [Related]
14. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
[TBL] [Abstract][Full Text] [Related]
15. Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients.
Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Chu Y; Chen S; Cao B; Su J; Duan Q; Zhang S; Shao H; Kong H; Gui B; Hu Z; Badal R; Xu Y
BMC Infect Dis; 2017 Dec; 17(1):776. PubMed ID: 29254478
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
Kiremitci A; Dinleyici EC; Erben N; Durmaz G; Yargic ZA; Aybey AD; Usluer G
Expert Opin Pharmacother; 2008 Jun; 9(9):1441-9. PubMed ID: 18518776
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activities of Eugenol and Cinnamaldehyde against the human gastric pathogen Helicobacter pylori.
Ali SM; Khan AA; Ahmed I; Musaddiq M; Ahmed KS; Polasa H; Rao LV; Habibullah CM; Sechi LA; Ahmed N
Ann Clin Microbiol Antimicrob; 2005 Dec; 4():20. PubMed ID: 16371157
[TBL] [Abstract][Full Text] [Related]
19. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
[TBL] [Abstract][Full Text] [Related]
20. [Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].
de Cueto M; Hernández JR; López-Cerero L; Morillo C; Pascual A
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):613-6. PubMed ID: 17194386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
